Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matti Suoniemi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|September 24, 2013
Lipidomics in drug discoveryTerhi Vihervaara, Matti Suoniemi, Reijo Laaksonen
Analytical and Bioanalytical Chemistry|January 26, 2015
Quantitative lysophospholipidomics in human plasma and skin by LC-MS/MSKaisa M Koistinen, Matti Suoniemi, Helena Simolin, et al.
Analytical Chemistry|August 8, 2013
Long-term performance and stability of molecular shotgun lipidomic analysis of human plasma samplesLaura A Heiskanen, Matti Suoniemi, Hung Xuan Ta, et al.
Analytical Chemistry|August 28, 2014
Differential mobility spectrometry-driven shotgun lipidomicsTuulia P I Lintonen, Paul R S Baker, Matti Suoniemi, et al.
The Journal of Clinical Endocrinology and Metabolism|November 19, 2013
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiencyKirill Tarasov, Kim Ekroos, Matti Suoniemi, et al.
Lipids in Health and Disease|August 12, 2015
Fish oil and krill oil differentially modify the liver and brain lipidome when fed to miceJon Skorve, Mika Hilvo, Terhi Vihervaara, et al.
Atherosclerosis|April 30, 2013
Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiencyMinna T Jänis, Kirill Tarasov, Hung Xuan Ta, et al.
Atherosclerosis|November 3, 2015
Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS studyJin M Cheng, Matti Suoniemi, Isabella Kardys, et al.
European Heart Journal|April 30, 2016
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterolReijo Laaksonen, Kim Ekroos, Marko Sysi-Aho, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|September 24, 2013
Lipidomics in drug discoveryTerhi Vihervaara, Matti Suoniemi, Reijo Laaksonen
Analytical and Bioanalytical Chemistry|January 26, 2015
Quantitative lysophospholipidomics in human plasma and skin by LC-MS/MSKaisa M Koistinen, Matti Suoniemi, Helena Simolin, et al.
Analytical Chemistry|August 8, 2013
Long-term performance and stability of molecular shotgun lipidomic analysis of human plasma samplesLaura A Heiskanen, Matti Suoniemi, Hung Xuan Ta, et al.
Analytical Chemistry|August 28, 2014
Differential mobility spectrometry-driven shotgun lipidomicsTuulia P I Lintonen, Paul R S Baker, Matti Suoniemi, et al.
The Journal of Clinical Endocrinology and Metabolism|November 19, 2013
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiencyKirill Tarasov, Kim Ekroos, Matti Suoniemi, et al.
Lipids in Health and Disease|August 12, 2015
Fish oil and krill oil differentially modify the liver and brain lipidome when fed to miceJon Skorve, Mika Hilvo, Terhi Vihervaara, et al.
Atherosclerosis|April 30, 2013
Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiencyMinna T Jänis, Kirill Tarasov, Hung Xuan Ta, et al.
Atherosclerosis|November 3, 2015
Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS studyJin M Cheng, Matti Suoniemi, Isabella Kardys, et al.
European Heart Journal|April 30, 2016
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterolReijo Laaksonen, Kim Ekroos, Marko Sysi-Aho, et al.
Pageof 1